chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient received vaccines in clinic. Stayed sitting for 5-7 minutes with no reaction. Offered for patient to wait in waiting room for mother to return but wanted to go find her in the grocery store (clinic is inside grocery store). Advised if and concerns or feeling off needs to come back. Was told from customer patient passed out after getting vaccine. Mother reported patient said he felt sick to stomach and then fell straight forward and was "out of it" for 1 min. Patient was examined by provider and EMS and was sent home. No further issues when checked on later in the day.
Systemic: Dizziness / Lightheadness-Mild, Systemic: Flushed / Sweating-Mild, Additional Details: few minutes after shot got warm , then her anxiety kicked in so she had a feeling of faintness---had her lie on floor, put fan on her for cooling & gave cold bottle of water--after a few more minutes felt well enough to sit back in chair--then waited remianing of 30 min & was ok after that to leave
pt recvd DTP/MMR/OPV vax 21JUL92 & devl lt deltoid hematoma, tender to touch @ site of inject, & 1 1/2 x 0.5 long urticarial rash about 2 cm below site of inject; swelling & urticaria improved w/cold compress;
I saw everything in blue for an hour, and then took a nap and it was fine. but it was extremely weird.
Patient was given Pfizer vaccine on 1/19/2021, returned to clinic today on 2/10/2021 and was given Moderna vaccine as 2nd dose.  patient was monitored for any reaction to medication, patient did not have any issues after vaccination.
COVID-19 Treatment; COVID-19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 62-year-old male patient received BNT162b2 (BNT162B2), on 19Apr2022 at 14:00 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 62 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Jun2022, outcome "unknown" and all described as "COVID-19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Jun2022) Negative; (Jun2022) Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: No other medication in 2weeks. anti viral COVID 19 Treatment Plaxovid, treatment start date 18Jun2022, treatment stop date 23Jun2022, adverse event Tested negative then after day 10 got sick again and tested positive. if patient recovered Not recovered, known allergies No and no other medical history.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
RECEIVED 1ST DOSE PFIZER COVID-19 VACCINE ON 02/12/21. REPORTED TO ER COMPLAINING OF RIGHT SIDE LOW BACK PAIN AND DAIGNOSED WITH ACUTE RIGHT-SIDED LOW BACK PAIN WITHOUT SCIATICA. DISCHARGED HOME AND INSTRUCTIONS TO FOLLOW UP AT BACK AND NECK PAIN CLINIC.
Egg size swollen lymph nodes under armpits, 3+ inch diameter red swollen hot and itchy lump at injection site, shortness of breath, chest pressure and pain, sharp pain and pressure lower part of neck near collar bones, headache, fatigue, brain fog
Vaccines given on 8/23/01 and had onset of bleeding symptoms on 8/25/01-8/26/01. Dx'd to have ITP on 8/27/01.
Information has been received from a physician concerning a 15 year old female who on 10-OCT-2007 was vaccinated with GARDASIL (lot # not specified). On approximately 07-DEC-2007, the patient was vaccinated intramuscularly with her second GARDASIL (lot#658556/1060U). There was no concomitant medication. On 10-DEC-2007 (2-3 days later), the patient experienced pain in right bicep (it was hard for her to write). 5-7 days after she was still experiencing pain. Unspecified medical attention was sought. The physician told her to take ADVIL as an anti-inflammatory. The patient's pain in right bicep persisted. No further information was provided. Additional information has been requested.
Patient developed a fever up to 105.0 over the course of 48 hours.  Had severe diarrhea, and became listless, not eating well, crying inconsolably.  She was hospitalized for several days, developed a UTI due to E. coli, and was placed on antibiotics and IV fluids. She has a follow up with a specialist to make sure her kidneys were not damaged.
This case was reported by a nurse via call center representative and described the occurrence of injection site erythema in a 61-year-old female patient who received FLULAVAL (batch number 93T79, expiry date June 2016). On 29th September 2015, the patient received FLULAVAL .5 ml. On 29th September 2015, several hours after receiving FLULAVAL, the patient experienced injection site erythema, injection site induration and injection site itching. On an unknown date, the outcome of the injection site erythema and injection site induration were recovering/resolving and the outcome of the injection site itching was not recovered/not resolved. The reporter considered the injection site erythema, injection site induration and injection site itching to be almost certainly related to FLULAVAL. Additional details provided were as follows: This case was reported by a nurse practitioner. This case was previously reported to a doctor. On 29th September 2015, in the morning (exact time unsure), the patient received a dose of FLULAVAL vaccine in left deltoid. In the evening of the same day (exact time unsure), the patient experienced redness and induration around the injection site and an itching at the injection site. The reporter prescribed washing site with warm water and soap for consumer.
breakthrough of covid with symptoms of mid fever, congestion, coughing, body aches. I was given Paxlovid medication.
r 1356  Pt c/o lips swelling, denies SOB or other s/s reaction. Benadryl given po. BP 130/76 P92 r185a029. Released Lungs clear, mild edema iulips. MM pink. Normal respiratory effort  p  1409 Pt states feels fine and needs to go to her doctor's appt. BP 120//80 p 88 r 18 1411 released stable condition go directly to pcp office
Patient received covid vaccine at local health department clinic on 02/25/2021 and presented to this reporters facility ED on 03/01/2021.  Patient with multiple comorbidities and newly diagnosed COPD presented after SOB not relieved by new rescue inhaler.  Admitted to hospital with pneumonia/sepsis.  Treated, improved and discharged to home
Severe muscle pain in legs. Difficulty walking. Feet feel heavy. Feet tingling and burning. Must wear insoles in shoes to walk. Lost balance at time. Trouble lifting over 10 lbs. Taking Alleve.
Several minutes after the shots were given the child coughed a congested sounding cough complained his tummy hurt, he leaned back on grandfather's lap body straight arms drew up, jaw tighten seizure like twitching, no urinary incontinence, all happened within about 1 minutes time.
Raised Injection Site after first booster; inflamed Injection Site for 2 days; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE SWELLING (Raised Injection Site after first booster) and VACCINATION SITE INFLAMMATION (inflamed Injection Site for 2 days) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 071F21A, 036A21A and 008B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 01-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Mar-2022, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021, the patient experienced VACCINATION SITE SWELLING (Raised Injection Site after first booster) and VACCINATION SITE INFLAMMATION (inflamed Injection Site for 2 days). On 14-Nov-2021, VACCINATION SITE SWELLING (Raised Injection Site after first booster) and VACCINATION SITE INFLAMMATION (inflamed Injection Site for 2 days) had resolved.            No concomitant medications were reported. No treatment information were provided.   This case was linked to MOD-2022-569419, MOD-2022-569365, MOD-2021-225686 (Patient Link).   Reporter did not allow further contact
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 35-year-old female patient (not pregnant) received BNT162b2 (COMIRNATY), on 31Oct2021 at 11:00 as dose 2, (booster)single (Lot number: 3203080) at the age of 35 years, in left arm for covid-19 immunisation; janssen coviD-19 vaccine (JANSSEN COVID-19 VACCINE), on 08Mar2021 at 08:00 as dose 1, single (Lot number: 1805022), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Hypertension" (unspecified if ongoing); "obesity" (unspecified if ongoing); "COPD" (unspecified if ongoing); "bronchitis" (unspecified if ongoing); "migraines" (unspecified if ongoing); "HSV2" (unspecified if ongoing); "ADD" (unspecified if ongoing); "ADHD" (unspecified if ongoing); "insomnia" (unspecified if ongoing). Concomitant medication(s) included: AMPHETAMINE; ADDERALL, start date: 01Jul2022, stop date: 19Jul2022; DEXTROAMPHETAMINE HYDROCHLORIDE, start date: 01Jul2022, stop date: 19Jul2022; LUNESTA, start date: 01Jul2022, stop date: 19Jul2022. Past drug history included: Prednisone, reaction(s): "known allergies: Prednisone", notes: known allergies: Prednisone. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2022, outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: Body temperature: (28Jul2022) 101. 5, notes: I had a fever of 101. 5; SARS-CoV-2 test: (2022) Unknown results, notes: I took Paxlovid to prevent developing severe Covid; (2022) Negative, notes: The medication made me very I'll immediately upon taking it but completed the full course and was Covid negative after 3 days; (2022) Positive, notes: However on the last date of taking the treatment, my Covid test came back positive. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical information: Patient received COVID 19 Treatment with Paxlovid start date was 19Jul2022 and stop date was 24Jul2022 indication was treatment of COVID-19. The patient now starting to feel nasal congestion, headaches, fatigue, brain fog, lethargic, hot/cold feeling inside, dizziness, nausea and cough is returning. I had a fever of 101. 5 today after going 4 days without one and not taking fever reducing Medicine. I am afraid I have rebound Covid and unsure how to address the symptoms or that I will not be able to fight this virus on my own. I'm feeling as sick as I felt on day one. My kids are also sick but we're not treated with Paxlovid. I am concerned over these symptoms and unsure what I can do.  No follow-up attempts are required. No further information is expected.
COUGH  ED to Hosp-Admission Discharged  3/5/2021 - 3/7/2021 (2 days) Hospital  DO Last attending ? Treatment team Rectal bleeding Principal problem Discharge Summary DO (Physician) ? ? Internal Medicine         HOSPITAL INPATIENT DISCHARGE SUMMARY HOSPITALIST GROUP .                                                              Date: 3/7/2021 Admission Date: 3/5/2021 Length of stay: 0 Days PCP: MD Discharging provider: DO    Discharge diagnosis:    Hospital Problems          POA   * (Principal) Rectal bleeding Yes       Glaucoma Yes       COVID-19 virus infection Yes   Overview Signed 3/5/2021 11:11 PM by  MD      Asymptomatic                Disposition: Home CODE STATUS (LOI): Full Code   Consulted Services: none    Hospital Course   HPI: Rectal bleeding     Hospital Course:   Patient was hospitalized bright red blood per rectum without evidence of acute blood loss anemia.  He has a history of radiation colitis with lastest unrevealing colonoscopy in December 2011.  He feelss improved with stable hemoglobin and did have normal bowel movement by next day.  Likely this is internal hemorrhoids, probably isolated; no intervention warranted.   Incidentally, patient had COVID positive but exhibits no symptoms.  No CXR obtained; he will have second vaccination shot in 2 days as per previous scheduled.   Disposition plan was discussed with patient's daughter over the phone on March 6.  Hemoglobin was 12.6 upon discharge on March 7 when patient was deemed stable to transition out of hospital.   _
A dark spot, It looks like a foreign object in there, It's adhered to the bottle; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT QUALITY ISSUE (A dark spot, It looks like a foreign object in there, It's adhered to the bottle) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 034F21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT QUALITY ISSUE (A dark spot, It looks like a foreign object in there, It's adhered to the bottle). At the time of the report, PRODUCT QUALITY ISSUE (A dark spot, It looks like a foreign object in there, It's adhered to the bottle) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided. No treatment medications were reported. It was reported that the vaccine expiration date as 01-JAN-1900.
Information has been received from an RN concerning an 18 year old female who on an unspecified date the pt was vaccinated with a 1st dose Hep-B vaccine and on an unspecified date the pt was vaccinated with a 2nd dose of Hep-B (MSD). Within 1 day, post vax, of the 1st and 2nd vaccination administration, the pt developed severe nausea, vomiting, diarrhea and a headache. The reporter stated that the reaction lasted approx. 10 days. The pt sought unspecified medical attention. On 7/27/00, the pt was vaccinated with the 3rd dose of Hep-B. Additional information has been requested.
tingling on hands/feet/arms/legs for the past 7 days(everyday, all days)  after 4th day from the inoculated date
During her last feeding of the night, she started arching her back. I thought she just wanted out of my lap and to be burped. I sat her up and she started having spasms where she would throw her hands behind her head and turn her head from side to side while her whole body would jerk. She had clusters of them. I thought she was having a seizure. Took her into the emergency room where the doctor told me she was having muscle spasms but nothing was wrong with her. We didn't do blood work or any sort of testing. I scheduled an appointment with our pediatrician who also said there was nothing wrong with her and referred us to a neurologist.
Information has been received from a pharmacist referring to a about 45 years old male patient. The patient had no drug reactions/allergies and no pertinent medical history. On unspecified dates in 2014, the patient was vaccinated with 2 doses of VARIVAX (Merck) (lot# and dose unknown) subcutaneously. No concomitant medication was reported. The patient had titers drawn on an unspecified date in February 2015 which were negative for immunity to varicella. As a result, patient was administered a third dose of VARIVAX (Merck) subcutaneously (extra dose administered) on an unspecified date in February 2015. The reporter considered the events as non-serious. Outcome and causality were not provided. No product quality issue (PQC) was involved. Additional information has been requested.
sore arm; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  An 83-year-old male patient received BNT162b2 (BNT162B2), on 25Jan2021 as dose 1, single (Lot number: EL9261) at the age of 83 years for covid-19 immunisation. The patient's relevant medical history included: "Meniere's disease" (unspecified if ongoing), notes: Meniere's disease years ago; "Had a reaction to penicillin" (unspecified if ongoing), notes: Had a reaction to penicillin many years ago and got a rash.; "rash" (unspecified if ongoing), notes: Had a reaction to penicillin many years ago and got a rash. There were no concomitant medications. The following information was reported: PAIN IN EXTREMITY (non-serious) with onset 2021, outcome "unknown", described as "sore arm".  Additional information: The caller reported that with the first one, he did not have any adverse effects, just a sore arm, which of course, was normal. Years ago, had Meniere's disease and they thought he had would get loss of balance and he used to take Antivert for that. The patient had a reaction to penicillin many years ago and got a rash. It was about 40 years ago. The patient's brother and wife both got the shots and had no problems. There were no additional vaccines administered on same date of the Pfizer suspect. There were no prior vaccinations (within 4 weeks). There were no relevant tests.
Pt recvd vax & was found to be a nonresponder, in AUG92, pt devel elevated liver enzymes; f/u test in DEC92 has shown the liver enzyme levels returning to nl;
Experiencing a side effect; When can he take ibuprofe and it not affect his immune response; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Experiencing a side effect) and IMMUNE SYSTEM DISORDER (When can he take ibuprofe and it not affect his immune response) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Experiencing a side effect) and IMMUNE SYSTEM DISORDER (When can he take ibuprofe and it not affect his immune response). At the time of the report, VACCINATION COMPLICATION (Experiencing a side effect) and IMMUNE SYSTEM DISORDER (When can he take ibuprofe and it not affect his immune response) outcome was unknown.
1-day post vaccine pt. presented w/ 2.5" large, red, swollen mass that was warm to the touch and painful. Sent pt to MD for f/u.
Itchy, swollen, red rash, sore arm with huge knot and very hot to the touch. Felt very sick next couple days with fatigue, fever, weak muscles. I used ice pack for a few days and Tylenol. Arm is still slightly sore with a mild redness. The redness gets a bit worse when I shower. No longer fatigued or weak muscles.
Prolonged weakness in arms and legs. Constant dizziness   I am an athlete and workout every dat. Since getting the vaccines I can bear lay finish a workout. My arms and especially my legs feel like jello half way thru the workout.
From telephone contact with patient's parent, it was stated that a 19-year-old male patient received a Menomune A/C/ Y/W-135 vaccination on 31-Jul-2001. Within 4-5 hours the patient was achy and experiencing pain in the joints. He developed a fever of 101.2 deg F., and a sore throat. Patient is going to physician to be evaluated.  From additional correspondence received on 05-Sep-2001 it was reported, "Patient contracted Mono from one of his friends happenstance at the same time. "No problem with Menomune"-father and pharmacist. This case is closed
This spontaneous report was received from a physician via an unspecified reporter referring to a patient of unknown age and gender. The patient's concurrent conditions and medical history were not reported. On 25-FEB-2016, the patient was vaccinated with a dose of improperly stored PNEUMOVAX 23 "10 PK 0.5mL SD-PFS-LLokwTip 10PK" and lot number L014876 with expiration date of 13-JAN-2017 (route of administration and anatomical location were not reported), which was stored at a lowest recorded temperature of 27F (-2.7 Celsius) for 456 hours. The vaccine status was reported as excursion and the storage criteria and the vaccine excursion were reported as "Refrigerator(R)". No concomitant therapies nor adverse effect were reported. No product quality complaint was involved. This is one of several cases from the same reporter. Additional information has been requested.
patient received an 11 th dose of ipv vaccine. Polio vials come in a 10th dose vials with additional vaccine residual. per sanofi pasteur and CDC guidelines ; Only the number of doses indicated in the manufacturer?s package insert should be  withdrawn from the vial. After the maximum number of doses have been withdrawn, the  vial should be discarded, even if there is residual vaccine or the expiration date has not  been reached. Pt parent has been made aware, pt is doing well, has no fever/rash/side effects. Due to the IPV vaccine incident. Center has implemented changes to prevent this error form happening again. Created a vaccine puncture log, in which every time we draw a dose from a multidose vaccine vial, we are documenting the dose umber on the log.  We all are aware to only draw the doses indicated by the manufactures package insert, After the maximum number of doses have been withdrawn, the vial will be discarded, even if there is residual vaccine.   The log is attached to each vaccine box.   All the personal who administers vaccines have been trained of these changes
This spontaneous report as received from a nurse refers to a patient of unknown age and gender. On 16-DEC-2015, the patient was vaccinated with a dose of VARIVAX (dose lot # and route were not provided) instead of ZOSTAVAX. The patient had not experienced any adverse effects. She did not known why the error was made. Additional information has been requested.
Information has been received from a physician via company representative concerning to a patient of unknown age and gender. Concurrent and historical conditions were not reported. Concomitant therapies were not provided. On 22-DEC-2014, the patient was vaccinated with an improperly stored dose of GARDASIL "10x 1 sdv" (lot No. K001631, exp. 06-NOV-2016) (dose and site not reported). On an unspecified date, the GARDASIL vaccine had two temperature excursions: 24 and 48 hours respectively. The lowest recorded temperature was 34. The highest recorded temperature was 47. The vaccine status was reported as "in excursion". The vaccine storage criteria and the vaccine excursion were reported as "Refrigerator(R)". No adverse effects were reported. There was no product quality complaint involved. This is one of several reports received from the same reporter. Additional information has been requested.
Petechial hemorrhage from waist down, bleeding gums and sever nose bleeds, Severe random angioedema.
I got my flu shot on October 14, the next day the dizziness started and got worse on Friday (Oct, 16). Now, I have some dizziness periods during the day, specially when I do some fast moving.